Page last updated: 2024-09-05

sorafenib and zm 336372

sorafenib has been researched along with zm 336372 in 3 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(zm 336372)
Trials
(zm 336372)
Recent Studies (post-2010) (zm 336372)
6,5207305,25127011

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)zm 336372 (IC50)
Receptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)100
RAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)0.0603
Proto-oncogene tyrosine-protein kinase LCK Mus musculus (house mouse)0.57
Serine/threonine-protein kinase B-rafHomo sapiens (human)0.23
Delta-type opioid receptorMus musculus (house mouse)0.18
Mitogen-activated protein kinase 11Homo sapiens (human)2
Mitogen-activated protein kinase 14Homo sapiens (human)1.09

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gray, NS; Liu, Y1
Alessi, DR; Arthur, JS; Bain, J; Cohen, P; Elliott, M; Hastie, CJ; Klevernic, I; McLauchlan, H; Plater, L; Shpiro, N1
Dotterweich, J; Einsele, H; Lohmeyer, J; Nerreter, T; Seggewiss-Bernhardt, R1

Other Studies

3 other study(ies) available for sorafenib and zm 336372

ArticleYear
Rational design of inhibitors that bind to inactive kinase conformations.
    Nature chemical biology, 2006, Volume: 2, Issue:7

    Topics: Binding Sites; Drug Design; Humans; Models, Molecular; Phosphotransferases; Protein Kinase Inhibitors; Protein Structure, Tertiary

2006
The selectivity of protein kinase inhibitors: a further update.
    The Biochemical journal, 2007, Dec-15, Volume: 408, Issue:3

    Topics: Amino Acid Sequence; Animals; Cell Line; Drug Design; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Recombinant Proteins; Spodoptera

2007
Sorafenib paradoxically activates the RAS/RAF/ERK pathway in polyclonal human NK cells during expansion and thereby enhances effector functions in a dose- and time-dependent manner.
    Clinical and experimental immunology, 2018, Volume: 193, Issue:1

    Topics: Apoptosis; Benzamides; Cell Degranulation; Cell Line; Cytokines; Extracellular Signal-Regulated MAP Kinases; Humans; Killer Cells, Natural; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; raf Kinases; ras Proteins; Signal Transduction; Sorafenib; Sunitinib

2018